Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith A Aberg

Showing results (181-190 of 212) with videos related to

Pageof 22
Sort By:
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
AIDS (London, England)|July 24, 2025
No evidence of pitavastatin effect on muscle area or density among people with HIVKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Contemporary Clinical Trials|December 3, 2022
The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trialEvelynne S Fulda, Carl J Fichtenbaum, Emma M Kileel, et al.
The Journal of Infectious Diseases|October 17, 2020
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Viruses|April 27, 2024
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog, Christoph D Spinner, Ulrike Protzer, et al.
The Lancet. HIV|April 5, 2026
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysisTriin Umbleja, Mohammad U Zafar, Sara McCallum, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2022
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United StatesMarkella V Zanni, Borek Foldyna, Sara McCallum, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.
Pageof 22

Showing results (181-190 of 212) with videos related to

Sort By:
Pageof 22
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
AIDS (London, England)|July 24, 2025
No evidence of pitavastatin effect on muscle area or density among people with HIVKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Contemporary Clinical Trials|December 3, 2022
The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trialEvelynne S Fulda, Carl J Fichtenbaum, Emma M Kileel, et al.
The Journal of Infectious Diseases|October 17, 2020
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Viruses|April 27, 2024
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog, Christoph D Spinner, Ulrike Protzer, et al.
The Lancet. HIV|April 5, 2026
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysisTriin Umbleja, Mohammad U Zafar, Sara McCallum, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2022
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United StatesMarkella V Zanni, Borek Foldyna, Sara McCallum, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.
Pageof 22